Faeth Therapeutics, Inc.
FTH- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001829802
In the last 90 days, Faeth Therapeutics, Inc. insiders filed 1 open-market purchase and 0 sales; 45 institutions reported holding it in 13F filings for Q2 2026, worth $333.8M in total; no superinvestor holds it.
13F holders, Q3 2023
Institutional positions in Faeth Therapeutics, Inc. as of Sep 30, 2023. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 23
- −2 vs. Q2 2023
- Shares held
- 3.11M
- −19.7K (−0.6%) vs. Q2 2023
- Total value
- $2.38M
- −$1.19M (−33.3%) vs. Q2 2023
- New holders
- 1
- 2 more added
- Sold out
- 3
- 7 more reduced
1 institution that held it in Q2 2023 haven't filed for Q3 2023 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q2 2023: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting FTH on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 45 | $333.8M |
| Q1 2026 | 30 | $68.0M |
| Q4 2025 | 10 | $514.8K |
| Q3 2025 | 9 | $466.2K |
| Q2 2025 | 10 | $600.0K |
| Q1 2025 | 20 | $760.2K |
| Q4 2024 | 24 | $1.16M |
| Q3 2024 | 19 | $1.32M |
| Q2 2024 | 24 | $1.31M |
| Q1 2024 | 25 | $2.43M |
| Q4 2023 | 24 | $2.05M |
| Q3 2023 | 23 | $2.38M |
| Q2 2023 | 26 | $3.58M |
| Q1 2023 | 27 | $4.71M |
| Q4 2022 | 28 | $3.93M |
| Q3 2022 | 31 | $4.47M |
| Q2 2022 | 40 | $7.06M |
| Q1 2022 | 43 | $8.21M |
| Q4 2021 | 38 | $19.7M |
| Q3 2021 | 42 | $37.1M |
| Q2 2021 | 34 | $22.7M |
| Q1 2021 | 40 | $45.8M |
Institutions, Q3 2023
Shares, value and share of portfolio for each institution holding Faeth Therapeutics, Inc.; share changes are against Q2 2023.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Newtyn Management, LLC | 1,800,000 | $1.35M | 0.33% | −27,240−1.5% | Reduced |
| Vanguard Group Inc | 573,651 | $458.9K | 0.00% | 00.0% | Unchanged |
| Geode Capital Management, LLC | 136,318 | $102.3K | 0.00% | +38,312+39.1% | Added |
| Bridgeway Capital Management, LLC | 112,900 | $84.7K | 0.00% | 00.0% | Unchanged |
| Duquesne Family Office LLCSuperinvestorDuquesne Family Office | 100,000 | $80.0K | 0.00% | 00.0% | Unchanged |
| Bank of America Corp | 90,774 | $72.6K | 0.00% | 00.0% | Unchanged |
| Renaissance Technologies LLC | 83,800 | $67.0K | 0.00% | −5,700−6.4% | Reduced |
| Millennium Management LLC | 57,309 | $43.0K | 0.00% | +3,099+5.7% | Added |
| BlackRock Inc. | 35,225 | $28.2K | 0.00% | −1,442−3.9% | Reduced |
| Northern Trust Corp | 26,049 | $20.8K | 0.00% | 00.0% | Unchanged |
| State Street Corp | 25,774 | $19.3K | 0.00% | 00.0% | Unchanged |
| Two Sigma Advisers, LP | 19,400 | $15.5K | 0.00% | −5,500−22.1% | Reduced |
| Raymond James & Associates | 14,000 | $11.2K | 0.00% | 00.0% | Unchanged |
| Deuterium Capital Management, LLC | 11,000 | $8.80K | 0.02% | 00.0% | Unchanged |
| Two Sigma Investments, LP | 10,876 | $8.70K | 0.00% | −2,700−19.9% | Reduced |
| Tower Research Capital LLC (TRC) | 7,259 | $5.81K | 0.00% | −211−2.8% | Reduced |
| Banque Cantonale Vaudoise | 3,900 | $3.00K | 0.00% | 00.0% | Unchanged |
| JPMorgan Chase & Co | 668 | $501 | 0.00% | 00.0% | Unchanged |
| Morgan Stanley | 219 | $175 | 0.00% | 00.0% | Unchanged |
| Wells Fargo & Company | 132 | $106 | 0.00% | 00.0% | Unchanged |
| Qube Research & Technologies Ltd | 4 | $3 | 0.00% | +4 | New |
| Harbour Investments, Inc. | 3 | $2 | 0.00% | 00.0% | Unchanged |
| Royal Bank of Canada | 247 | $0 | 0.00% | −225−47.7% | Reduced |
| Dimensional Fund Advisors LP | 0 | $0 | 0.00% | −11,570−100.0% | Sold out |
| UBS Group AG | 0 | $0 | 0.00% | −6,511−100.0% | Sold out |
| FMR LLC | 0 | $0 | 0.00% | −8−100.0% | Sold out |
| BFT Financial Group, LLC | – | – | – | – | Not filed |